Project Grant R01CA315524
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $586K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $633,089 to The University of Texas MD Anderson Cancer Center on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate a novel cell stress response mechanism in pancreatic ductal adenocarcinoma (PDAC) that enables cancer cells to adapt to adverse microenvironmental conditions and evade immune surveillance. The research will identify and characterize immunotherapeutic...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $579,658 on August 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to investigate immune dynamics in metastatic renal cell carcinoma to bone. The research illuminates the bone metastatic microenvironment in clear cell renal cell carcinoma, which accounts for approximately 80 percent of renal malignancies and occurs in approximately 40 percent of metastatic patients. MD...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $688,073 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop computational approaches that reconstruct the evolutionary history of cancer metastases. The project, led by Dr. Peter Van Loo, applies molecular archeology of cancer methods—DNA sequencing-based approaches that infer tumor evolutionary history—to metastatic disease. The work will advance understanding of how...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $164,000 on July 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to characterize osteosarcoma-specific CD24 glycosylation profiles and facilitate development of glycoform-targeted therapeutic antibodies. The research addresses metastatic osteosarcoma, where approximately 40 percent of patients relapse with pulmonary metastatic disease despite aggressive treatment. CD24, a...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $706,739 on June 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to unravel the molecular mechanisms of immunotherapy-associated myocarditis. The research investigates how immune checkpoint inhibitors, which enhance anti-tumor immune responses in cancer treatment, trigger myocarditis—inflammation of the heart that carries mortality rates up to 50 percent. The project uses mouse models...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $621,632 on June 17, 2026, under the Cancer Treatment Research program (CFDA 93.395) to elucidate the molecular and metabolic mechanisms underlying disulfidptosis and therapeutically target this form of regulated cell death in SLC7A11-high cancers. The research employs human cancer cell lines and integrated cell-based molecular analyses including metabolomics, proteomics, CRISPR screening, and biochemical...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $671,740 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to define biomarkers and overcome resistance to DLL3-targeting immune therapies in small cell lung cancer. The research focuses on understanding tumor-intrinsic and immune-related mechanisms of response and resistance to delta-like ligand 3 (DLL3)-targeting T-cell engagers, particularly following the FDA approval of...
- The National Cancer Institute awarded the University of Texas MD Anderson Cancer Center $645,865 on July 1, 2026, under Cancer Biology Research (CFDA 93.396) to investigate how perineural invasion in cutaneous squamous cell carcinoma drives immunotherapy resistance through neuroimmune mechanisms. The research addresses the molecular pathway linking nerve invasion to tumor immune suppression. The project will investigate how activating transcription factor 3 (ATF3)-dependent transcriptional...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $2.64M project grant under the Cancer Biology Research program (CFDA 93.396) to The University of Texas MD Anderson Cancer Center for a four-year study (August 1, 2025 – July 31, 2029) investigating age-related increases in omental metastatic competence in ovarian cancer patients. The research will identify mechanisms by which aging enhances the omentum's susceptibility to cancer cell colonization and develop...